ALKS

ALKS

USD

Alkermes plc Ordinary Shares

$30.480+0.480 (1.600%)

リアルタイム価格

Healthcare
Drug Manufacturers - Specialty & Generic
アイルランド

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$30.000

高値

$30.630

安値

$29.770

出来高

0.42M

企業ファンダメンタルズ

時価総額

5.0B

業種

Drug Manufacturers - Specialty & Generic

Ireland

取引統計

平均出来高

2.00M

取引所

NMS

通貨

USD

52週レンジ

安値 $25.17現在値 $30.480高値 $36.45

関連ニュース

Analyst Upgrades

Wells Fargo Maintains Overweight on Alkermes, Lowers Price Target to $42

Wells Fargo analyst Benjamin Burnett maintains Alkermes with a Overweight and lowers the price target from $44 to $42.

もっと見る
Wells Fargo Maintains Overweight on Alkermes, Lowers Price Target to $42
Analyst Upgrades

Needham Maintains Buy on Alkermes, Raises Price Target to $44

Needham analyst Ami Fadia maintains Alkermes with a Buy and raises the price target from $43 to $44.

もっと見る
Needham Maintains Buy on Alkermes, Raises Price Target to $44
PR Newswire

Alkermes plc Reports Third Quarter 2025 Financial Results

Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2025. "Alkermes delivered another successful quarter, achieving ...

もっと見る
Alkermes plc Reports Third Quarter 2025 Financial Results
Analyst Upgrades

Mizuho Maintains Outperform on Alkermes, Raises Price Target to $45

Mizuho analyst Uy Ear maintains Alkermes with a Outperform and raises the price target from $40 to $45.

もっと見る
Mizuho Maintains Outperform on Alkermes, Raises Price Target to $45
Analyst Upgrades

Piper Sandler Reiterates Overweight on Alkermes, Raises Price Target to $45

Piper Sandler analyst David Amsellem reiterates Alkermes with a Overweight and raises the price target from $38 to $45.

もっと見る
Piper Sandler Reiterates Overweight on Alkermes, Raises Price Target to $45
Analyst Upgrades

RBC Capital Maintains Outperform on Alkermes, Raises Price Target to $47

RBC Capital analyst Leonid Timashev maintains Alkermes with a Outperform and raises the price target from $45 to $47.